L-MDAM
Alternative Names: Gamma-Methylene-10-deazaminopterin; L-gamma-Methylene-10-deazaminopterin; MDAMLatest Information Update: 04 Nov 2017
At a glance
- Originator University of South Alabama
- Developer BioNumerik Pharmaceuticals
- Class
- Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV)
- 01 May 2007 This programme is still in active development
- 26 Jun 2000 A phase I study in patients with solid tumours has been added to the therapeutic trials, adverse events and pharmacokinetics sections